Ligand’s Technologies Support Potential Coronavirus Treatments

Ligand Pharmaceuticals (NASDAQ:LGND) announced that its proprietary technologies are being utilized by partners to enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China.

As quoted in the press release:

Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms.

Ligand partner Gilead Sciences’ Captisol-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first case of 2019 novel coronavirus in the United States¹. Gilead Sciences stated that while there are no antiviral data for remdesivir that show activity against 2019-nCoV at this time, there are available data in other coronaviruses. Remdesivir is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Click here to read the full press release.